Status:
NOT_YET_RECRUITING
Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)
Lead Sponsor:
AstraZeneca
Conditions:
Neurofibromatosis Type 1
Eligibility:
All Genders
Brief Summary
Neurofibromatosis type 1 (NF1), a genetic disorder, results from NF1 gene mutations with nearly complete penetrance (1). NF1 is considered common as a rare disease; it has a birth incidence of approxi...
Eligibility Criteria
Inclusion
- A. Male or female patients of any age at index date (first diagnosis of NF1 and/or PN).
- B. Have been diagnosed with NF1 according to the NIH Consensus Development Conference diagnostic criteria or the revised criteria between 01-Jan- 2010 and 31-December-2023.
Exclusion
- A. Missing NF1 diagnosis data in their medical record.
Key Trial Info
Start Date :
December 10 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT07221331
Start Date
December 10 2025
End Date
September 30 2026
Last Update
October 27 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.